









Markets
/
Stocks
/
nasdaq-xtlb
/

X T L Biopharmaceuticals Ltd

XTLB

1.070USD

+0.010+0.94%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

9.43MMarket Cap

LossP/E TTM



X T L Biopharmaceuticals Ltd

1.070

+0.010+0.94%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of X T L Biopharmaceuticals Ltd

Currency: USD Updated: 2026-02-06

Key Insights

X T L Biopharmaceuticals Ltd's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 225 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend up.Despite strong stock market performance and technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

X T L Biopharmaceuticals Ltd's Score

Industry at a Glance

Industry Ranking

225 / 392

Overall Ranking

470 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

X T L Biopharmaceuticals Ltd Highlights

StrengthsRisks

X T L Biopharmaceuticals Ltd (Xenograft Technologies Ltd) is an Israel-based biopharmaceutical company engaged in acquisition and development of pharmaceutical drugs for treatment of autoimmune diseases. The Company pipelines include hCDR1 systematic lupus erythematosus and recombinant human erythropoietin (rHuEPO) multiple myeloma. Its hCDR1, which is a potential treatment for systemic lupus erythematosus (SLE) and Sjogren's syndrome (SS). hCDR1 is a peptide that is administered subcutaneously and acts as a disease-specific treatment to modify the SLE-related autoimmune process. The rHuEPO known agent for anemia to prolong a survival of patients for treatment of multiple myeloma blood cancer. Its Erythropoietin (EPO) is a glycoprotein hormone produced mainly by kidneys. EPO stimulates erythropoiesis, production of red blood cells, by binding to its receptor on a surface of erythroid progenitor cells, promoting their proliferation and differentiation and maintaining their viability.

Growing

The company is in a growing phase, with the latest annual income totaling USD 451.00K.

Overvalued

The company’s latest PE is -1.45, at a high 3-year percentile range.

Analyst Rating

Based on 0 analysts

Current Rating

0.000

Target Price

0.00%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of X T L Biopharmaceuticals Ltd is 4.49, ranking 389 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

4.49

Change



Financials

4.63

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

4.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

4.81

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

5.00

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

X T L Biopharmaceuticals Ltd's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of X T L Biopharmaceuticals Ltd is 7.47, ranking 117 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.45, which is -100.00% below the recent high of 0.00 and -3224.21% above the recent low of -48.26.

Score

Industry at a Glance

Previous score

7.47

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 225/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

No earnings forecast score is currently available for X T L Biopharmaceuticals Ltd. The Biotechnology & Medical Research industry's average is 8.05.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of X T L Biopharmaceuticals Ltd is 7.40, ranking 75 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 1.46 and the support level at 0.64, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.40

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.029

Buy

RSI(14)

62.110

Neutral

STOCH(KDJ)(9,3,3)

78.732

Buy

ATR(14)

0.135

High Vlolatility

CCI(14)

99.102

Neutral

Williams %R

11.189

Overbought

TRIX(12,20)

0.789

Sell

StochRSI(14)

98.123

Overbought

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

0.974

Buy

MA10

0.925

Buy

MA20

0.931

Buy

MA50

0.838

Buy

MA100

0.999

Buy

MA200

1.162

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Rabinovitch (Alexander)

1.46M

+120.96%

Klinger (Roy)

862.29K

Klinger (Tal)

862.29K

Yaacobi (Yaron)

450.00K

Noked Capital Ltd.

198.89K

Rhumbline Advisers Ltd. Partnership

17.26K

Morgan Stanley & Co. LLC

10.01K

-9.08%

Geode Capital Management, L.L.C.

8.90K

Turgeman (Doron)

3.40K

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of X T L Biopharmaceuticals Ltd is 1.36, ranking 323 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 1.13. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.